"Lipoproteins, VLDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of lipoproteins of very light (0.93-1.006 g/ml) large size (30-80 nm) particles with a core composed mainly of TRIGLYCERIDES and a surface monolayer of PHOSPHOLIPIDS and CHOLESTEROL into which are imbedded the apolipoproteins B, E, and C. VLDL facilitates the transport of endogenously made triglycerides to extrahepatic tissues. As triglycerides and Apo C are removed, VLDL is converted to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LOW-DENSITY LIPOPROTEINS from which cholesterol is delivered to the extrahepatic tissues.
| Descriptor ID |
D008079
|
| MeSH Number(s) |
D10.532.599 D12.776.521.622
|
| Concept/Terms |
Lipoproteins, VLDL- Lipoproteins, VLDL
- VLDL Lipoproteins
- Prebeta-Lipoproteins
- Prebeta Lipoproteins
- Very-Low-Density Lipoproteins
- Lipoproteins, Very-Low-Density
- Very Low Density Lipoproteins
- Pre-beta-Lipoproteins
- Pre beta Lipoproteins
|
Below are MeSH descriptors whose meaning is more general than "Lipoproteins, VLDL".
Below are MeSH descriptors whose meaning is more specific than "Lipoproteins, VLDL".
This graph shows the total number of publications written about "Lipoproteins, VLDL" by people in this website by year, and whether "Lipoproteins, VLDL" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lipoproteins, VLDL" by people in Profiles.
-
Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study. Vascul Pharmacol. 2019 05; 116:8-15.
-
Dietary protein restriction reduces circulating VLDL triglyceride levels via CREBH-APOA5-dependent and -independent mechanisms. JCI Insight. 2018 11 02; 3(21).
-
GLP-2 Dysregulates Hepatic Lipoprotein Metabolism, Inducing Fatty Liver and VLDL Overproduction in Male Hamsters and Mice. Endocrinology. 2018 09 01; 159(9):3340-3350.
-
Hepatitis B virus inhibits the in vivo and in vitro synthesis and secretion of apolipoprotein C3. Lipids Health Dis. 2017 Nov 13; 16(1):213.
-
GLP-1 Elicits an Intrinsic Gut-Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance. Arterioscler Thromb Vasc Biol. 2017 12; 37(12):2252-2259.
-
AUP1 (Ancient Ubiquitous Protein 1) Is a Key Determinant of Hepatic Very-Low-Density Lipoprotein Assembly and Secretion. Arterioscler Thromb Vasc Biol. 2017 04; 37(4):633-642.
-
Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. Am J Cardiol. 2005 Nov 01; 96(9):1266-72.
-
Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity. Metabolism. 2002 Apr; 51(4):409-18.